文献速递癫痫神经肌肉病

新发癫痫及酶诱导型与非酶诱导型抗癫痫药物与骨质疏松发生的独立关联

Independent Associations of Incident Epilepsy and Enzyme-Inducing and Non-Enzyme-Inducing Antiseizure Medications With the Development of Osteoporosis.
PubMed 文献 · JAMA Neurol · 2023-01-01

这项开放队列研究纳入1998至2019年6275例新发成人癫痫患者,中位随访5年。控制骨质疏松危险因素后,新发癫痫与骨质疏松发生时间加快41%独立相关(TR 0.59),酶诱导型抗癫痫药物与非酶诱导型抗癫痫药物也分别独立相关(TR 0.91与0.77)。作者认为应考虑对所有癫痫患者进行常规筛查和预防。

要点

  • 新发癫痫与骨质疏松风险独立相关,发生时间加快41%(TR 0.59)。
  • 酶诱导型抗癫痫药物独立相关,骨质疏松发生时间加快9%(TR 0.91)。
  • 非酶诱导型抗癫痫药物独立相关,发生时间加快23%(TR 0.77)。

核心结论

  • 新发癫痫与骨质疏松风险存在独立的临床意义显著的关联,酶诱导型和非酶诱导型抗癫痫药物也均独立相关。
  • 作者认为应考虑对所有癫痫患者进行常规筛查和预防。

研究设计与样本

  • 开放队列研究,覆盖1998至2019年,中位随访5年(IQR 1.7-11.1年)。
  • 数据来自临床实践研究数据链和医院电子健康记录,纳入6275例新发成人癫痫患者(女性3220例,51%;男性3055例,49%),中位年龄56岁(IQR 38-73岁)。
  • 暴露为新发成人癫痫(采用5年洗脱期)及连续接受4种抗癫痫药物。
  • 结局为新发骨质疏松,采用Cox比例风险或加速失效时间模型分析,新发癫痫作为时变协变量。

主要发现

  • 控制骨质疏松危险因素后,新发癫痫与骨质疏松发生时间加快41%独立相关(时间比TR 0.59;95%CI 0.52-0.67;P < .001)。
  • 酶诱导型抗癫痫药物与骨质疏松发生时间加快9%独立相关(TR 0.91;95%CI 0.87-0.95;P < .001)。
  • 非酶诱导型抗癫痫药物与骨质疏松发生时间加快23%独立相关(TR 0.77;95%CI 0.76-0.78;P < .001)。
  • 在倾向评分匹配分析、限制于成人起病癫痫的队列以及限制于晚发性癫痫的队列中,上述独立关联保持一致。

临床怎么用

  • 作者认为,应考虑对所有癫痫患者进行常规筛查和预防。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Both epilepsy and enzyme-inducing antiseizure medications (eiASMs) having varying reports of an association with increased risks for osteoporosis. OBJECTIVE: To quantify and model the independent hazards for osteoporosis associated with incident epilepsy and eiASMS and non-eiASMs. DESIGN, SETTING, AND PARTICIPANTS: This open cohort study covered the years 1998 to 2019, with a median (IQR) follow-up of 5 (1.7-11.1) years. Data were collected for 6275 patients enrolled in the Clinical Practice Research Datalink and from hospital electronic health records. No patients who met inclusion criteria (Clinical Practice Research Datalink-acceptable data, aged 18 years or older, follow-up after the Hospital Episode Statistics patient care linkage date of 1998, and free of osteoporosis at baseline) were excluded or declined. EXPOSURE: Incident adult-onset epilepsy using a 5-year washout and receipt of 4 consecutive ASMs. MAIN OUTCOMES AND MEASURES: The outcome was incident osteoporosis as determined through Cox proportional hazards or accelerated failure time models where appropriate. Incident epilepsy was treated as a time-varying covariate. Analyses controlled for age, sex, socioeconomic status, cancer, 1 or more years of corticosteroid use, body mass index, bariatric surgery, eating disorders, hyperthyroidism, inflammatory bowel disease, rheumatoid arthritis, smoking status, falls, fragility fractures, and osteoporosis screening tests. Subsequent analyses (1) excluded body mass index, which was missing in 30% of patients; (2) applied propensity score matching for receipt of an eiASM; (3) restricted analyses to only those with incident onset epilepsy; and (4) restricted analyses to patients who developed epilepsy at age 65 years or older. Analyses were performed between July 1 and October 31, 2022, and in February 2023 for revisions. RESULTS: Of 8 095 441 adults identified, 6275 had incident adult-onset epilepsy (3220 female [51%] and 3055 male [49%]; incidence rate, 62 per 100 000 person-years) with a median (IQR) age of 56 (38-73) years. When controlling for osteoporosis risk factors, incident epilepsy was independently associated with a 41% faster time to incident osteoporosis (time ratio [TR], 0.59; 95% CI, 0.52-0.67; P < .001). Both eiASMs (TR, 0.91; 95% CI, 0.87-0.95; P < .001) and non-eiASMs (TR, 0.77; 95% CI, 0.76-0.78; P < .001) were also associated with significant increased risks independent of epilepsy, accounting for 9% and 23% faster times to development of osteoporosis, respectively. The independent associations among epilepsy, eiASMs, and non-eiASMs remained consistent in propensity score-matched analyses, cohorts restricted to adult-onset epilepsy, and cohorts restricted to late-onset epilepsy. CONCLUSIONS AND RELEVANCE: These findings suggest that epilepsy is independently associated with a clinically meaningful increase in the risk for osteoporosis, as are both eiASMs and non-eiASMs. Routine screening and prophylaxis should be considered in all people with epilepsy.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Josephson CB, Gonzalez-Izquierdo A, Denaxas S, et al. Independent Associations of Incident Epilepsy and Enzyme-Inducing and Non-Enzyme-Inducing Antiseizure Medications With the Development of Osteoporosis. JAMA Neurol. 2023. PMID: 37306981. doi:10.1001/jamaneurol.2023.1580

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。